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Identity 
Other names: SIP; TEAP; p53DINP1; TP53INP1A; 
TP53INP1B; TP53DINP1 




Gene is ~24 kb, with 5 exons. 
Transcription 
Alternative splicing: 2 transcripts: TP53INP1alpha 
(exons 1, 2, 3, 4 and 5 with a stop codon in the fourth 
exon) and TP53INP1beta (exons 1, 2, 3 and 5 with a 
stop codon in the fifth exon). 
Protein 
Description 
2 isoforms: TP53INP1alpha, 18 kDa (164 amino acids) 
and TP53INP1beta, 27 kDa (240 amino acids). Both 
isoforms contain a PEST domain (sequence rich in 
proline, glutamic acid, serine and threonine between 
amino acids 26 and 62 found in proteins with half-lives 
of less than 2 h). 
Expression 
In mouse: TP53INP1 is expressed in thymus, spleen 
and bone marrow. It is also expressed at low levels in 
heart, stomach, liver, intestine, testis, kidney and 
pancreas. TP53INP1 expression is highly induced 
during the acute phase of mouse experimental 
pancreatitis (caerulein induced). 
In cells lines: TP53INP1 is transcriptionally induced in 
response to stress in a p53-dependent and independent 
manner. Examples: in mouse fibroblast, it is induced 
upon adriamycin, methyl-methane sulfonate, ethanol, 
H2O2, UV exposure and heat shock treatment; in 
neuronal cells by copper treatment; in pancreatic cancer 
cell lines by gemcitabine; in pro-B cells by IL-3 
deprivation or treatement with staurosporine, cisplatin, 
campto-thecin, methotrexate and paclitaxel; in mouse 
embryonic fibroblast (MEF), human fibroblasts and 
MCF7 by gamma irradiation; in melanoma cells by UV 
mimetic compound (4NQ). 
TP53INP1 expression is regulated by different 
transcriptional regulators: p53, E2F1, p73 (in p53-/- 
cells), myc (in neuroblastoma cell lines) and PLZF (in 
hematopoietic cell lines). 
Localisation 
Nuclear when over-expressed and in PML-bodies 
(Promyelocytic leukemia protein) upon PML-IV over-
expression. 
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Green boxes: exons, black lines: introns, alternative splicing for TP53INP1beta in black and TP53INP1alpha in red. 
 
Function 
TP53INP1 is a tumor suppressor gene induced with 
different stress conditions. TP53INP1 overexpres-sion 
leads to cell cycle arrest (G1 phase) and p53-dependent 
or independent apoptosis. TP53INP1 interacts with p53 
and two kinases (HIPK2, and PKCd). These kinases 
phosphorylate p53 on serine 46 modifying the p53 
activity. TP53INP1 can modulate the p53 and p73 
transcriptional activity to potentiate pro-apoptotic 
pathways. Colitis and colitis-associated cancer are 
exacerbated in mice deficient for TP53INP1. 
Homology 
TP53INP1 is conserved between species (from fly to 
human). In vertebrates, one paralog has been identified, 
TP53INP2 localized on chromosome 20q11.2. 
TP53INP2 is involved in autophagy. 
Mutations 
Note 




TP53INP1 is lost early during pancreatic cancer 
progression (from the neoplasia stages PanIN2). This 
downregulation seems to be important for tumour 
development. TP53INP1 expression is down regulated 
by the oncogenic micro-RNA miR-155 during 
pancreatic cancer progression. 
Disease 
Sporadic cancer, very aggressive, epigenetic disease 
with known mutations/deletions of p53, K-Ras, 
SMAD4, p16, BRCA2, EGFR and HER2. 
Prognosis 
Very bad, with only 20% of patients reaching two years 





TP53INP1 expression is lost during breast cancer 
development. 
Disease 
Mainly in female (only 1% in male). Genetic disorders 
known: loss of HER2 and ER expression, mutations in 
p53 and BRCA1. 
Prognosis 
Mortality rate: 25%. 
Gastric cancer 
Note 
TP53INP1 expression is lost during cancer 
development. The decreased expression of TP53INP1 
protein may reflect the malignant grade of gastric 
cancer. 
Disease 
10% are familial. Mutations in APC, p53, Bcl-2. 
Prognosis 
The 5-year survival after surgical resection is 30-50% 
for patients with stage II and 10-25% for patients with 
stage III. 
Anaplastic carcinoma of the thyroid 
(ATC) 
Note 
TP53INP1 is overexpressed in anaplastic thyroid 
carcinoma. 
Disease 
ATC is less than 2% of total thyroid cancer but 
represents 40% of death by thyroid cancer. It is a very 
aggressive cancer with early dissemination. 
Prognosis 
5-year survival rate is less than 10%. 
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